For people seeking help with addiction, access to accurate information can be life-saving. Misleading ads risk delaying care and exploiting families at their most vulnerable moments.  When searching for treatment (or anything else) online, the Federal Trade Commission (FTC) advises: Recognize ads.  The first two or three search results are often paid or “sponsored” listings. These may not lead to the organization you intended to find. Verify contact information.  Don’t assume

Cannabis use in the United States has increased significantly in recent years, alongside rapidly evolving state policies that permit medical or recreational use. These shifts raise important questions about public health, including the impact on mental health and substance use disorder risk, adolescent brain development, and the potential harms associated with regular or high-potency use. Variations in state laws create a complex landscape that can influence access, perceptio

September is National Recovery Month, a time to come together and celebrate the strength, resilience, and hope of the millions of...

In a new study published in The New England Journal of Medicine , researchers with JCOIN’s Massachusetts Clinical Research Center found that providing medications for opioid use disorder (MOUD) during incarceration can improve outcomes and save lives after release. The study shows that individuals who received MOUD in jail were more likely to engage in treatment and less likely to experience an overdose within six months of release. The study evaluated the impact of a 2019 Ma

Study using AI to analyze community coalition meeting minutes from the HEALing Communities Study (HCS) identifies key themes and how they intersected with decisions when selecting evidence-based practices (EBPs) to reduce overdose deaths.

A study  published in JAMA Network Open  examined pharmacy barriers faced by patients prescribed buprenorphine to treat opioid use disorder (OUD) through telemedicine. The findings show that pharmacy-related challenges were common, with nearly one-third of study participants (31.9%) reporting going without buprenorphine at some point in the prior 12 months due to pharmacy-related barriers. Researchers surveyed 601 adults who were receiving treatment from a multistate telemedi